Loading clinical trials...

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT01670266

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

The primary objective of this study is to evaluate the safety and tolerability of 3 planned doses of ONO-9054 in the eyes of adult male and female patients with ocular hypertension (OHT) or mild open ...

Lead sponsor: Ono Pharma USA Inc•3 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

TERMINATEDPhase 1/2

Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension

NCT02226094 · Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT)

COMPLETEDPhase 2

AL-54478 Proof of Concept Study

NCT01318252 · Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 3, 2013Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment60

Start dateAug 2012

Last updatedJun 3, 2013

Condition

Ocular Hypertension (OHT)Mild Open Angle-glaucoma (OAG)

Locations shown

Costa Mesa Clinical Site

Costa Mesa, California

Newport Beach (satellite site)

Newport Beach, California

Santa Ana (satellite site)

Santa Ana, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 3, 2013Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions